SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Edward H. Lin, Heinz-Josef Lenz, Mansoor N. Saleh, Mary J. Mackenzie, James A. Knost, Kumudu Pathiraja, Ronald B. Langdon, Siu-Long Yao, Brian D. Lu, A randomized, phase II study of the anti-insulin-like growth factor receptor type 1 (IGF-1R) monoclonal antibody robatumumab (SCH 717454) in patients with advanced colorectal cancer, Cancer Medicine, 2014, 3, 4
  2. 2
    Helen King, Tamara Aleksic, Paul Haluska, Valentine M. Macaulay, Can we unlock the potential of IGF-1R inhibition in cancer therapy?, Cancer Treatment Reviews, 2014,

    CrossRef

  3. 3
    J. R. Strosberg, J. A. Chan, D. P. Ryan, J. A. Meyerhardt, C. S. Fuchs, T. Abrams, E. Regan, R. Brady, J. Weber, T. Campos, L. K. Kvols, M. H. Kulke, A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors, Endocrine Related Cancer, 2013, 20, 3, 383

    CrossRef

  4. 4
    Miral R Sadaria, Ralph H Hruban, Barish H Edil, Advancements in pancreatic neuroendocrine tumors, Expert Review of Gastroenterology & Hepatology, 2013, 7, 5, 477

    CrossRef

  5. 5
    Pavan Mankal, Eileen O'Reilly, Sunitinib malate for the treatment of pancreas malignancies – where does it fit?, Expert Opinion on Pharmacotherapy, 2013, 14, 6, 783

    CrossRef

  6. 6
    Steven K. Libutti, Therapy: Blockade of IGF-1R—not effective in neuroendocrine tumours, Nature Reviews Endocrinology, 2013, 9, 7, 389

    CrossRef

  7. 7
    Ulf Petrausch, Peter Markus Deckert, Monoclonal Antibody Cancer Treatments in Phase III Clinical Trials,